Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.

Abstract: Accurate diagnosis of clinically significant prostate cancer (csPCa) is central to patient management, with the clinical gold standard relying on the interpretation of multi-parametric ...

Alam frames PHI and MRI as noninvasive tools that help refine risk before proceeding to biopsy. In this video, Ridwan I. Alam, MD, MPH, discusses how the Prostate Health Index (PHI) performs alongside ...

ABSTRACT: Introduction: Prostate cancer (PC) is a malignant proliferation of prostate cells. Common screening methods, such as digital rectal examination and prostate-specific antigen (PSA) testing, ...

Prostate MRI currently lacks the accuracy to replace biopsies in active surveillance for prostate cancer. The negative predictive value of MRI remains below 90%, the general goal for safely avoiding ...

To evaluate the diagnostic performance of version 2.1 of the prostate imaging reporting and data system (PI-RADS v2.1) compared to version 2.0 (PI-RADS v2.0) for detecting clinically significant ...

We performed a post hoc analysis of a single-center phase II trial (ClinicalTrials.gov identifier: NCT03503643) in which patients with unilateral grade group (GG) 2-4 PCa (n = 108) underwent hemigland ...

Objective: To evaluate the diagnostic value of prostate-specific antigen (PSA) density, digital rectal examination (DRE), and family history in predicting prostate cancer among patients with low-risk ...

An artificial intelligence system slightly outperformed radiologists using PI-RADS at detecting clinically significant prostate cancer. A trained artificial intelligence (AI) system discriminated ...

PSMA-based PET imaging in newly diagnosed, high-risk localized prostate cancer, a National Cancer Institute (NCI) Cancer Moonshot trial. This is an ASCO Meeting Abstract from the 2025 ASCO ...

An MRI radiomics model for predicting a prostate-specific antigen response following abiraterone treatment in patients with metastatic castration-resistant prostate cancer Yi Wu Xiang Liu Shaoxian ...